Cytokine, Chemokine, and Metalloprotease Activation in the Serum of Patients with Nephropathia Epidemica from the Republic of Tatarstan and the Republic of Mordovia, Russia

Nephropathia Epidemica (NE), endemic to several Volga regions of Russia, including the Republic of Tatarstan (RT) and the Republic of Mordovia (RM), is a mild form of hemorrhagic fever with renal syndrome caused by infection with rodent-borne orthohantaviruses. Although NE cases have been reported for decades, little is known about the hantavirus strains associated with human infection in these regions. There is also limited understanding of the pathogenesis of NE in the RT and the RM. To address these knowledge gaps, we conducted comparative analyses of patients with NE in the RT and the RM. Clinical symptoms were more severe in patients with NE from the RM with longer observed duration of fever symptoms and hospitalization. Analysis of patient sera showed changes in the levels of numerous cytokines, chemokines, and matrix metalloproteases (MMPs) in patients with NE from both the RT and the RM, suggesting leukocyte activation, extracellular matrix degradation, and leukocyte chemotaxis. Interestingly, levels of several cytokines were distinctly different between patients NE from the RT when compared with those from the RM. These differences were not related to the genetic variation of orthohantaviruses circulating in those regions, as sequence analysis showed that Puumala virus (PUUV) was the causative agent of NE in these regions. Additionally, only the “Russia” (RUS) genetic lineage of PUUV was detected in the serum samples of patients with NE from both the RT and the RM. We therefore conclude that differences in serum cytokine, chemokine, and MMP levels between the RT and the RM are related to environmental factors and lifestyle differences that influence individual immune responses to orthohantavirus infection.

Membrane Microvesicles as Potential Vaccine Candidates

The prevention and control of infectious diseases is crucial to the maintenance and protection of social and public healthcare. The global impact of SARS-CoV-2 has demonstrated how outbreaks of emerging and re-emerging infections can lead to pandemics of significant public health and socio-economic burden. Vaccination is one of the most effective approaches to protect against infectious diseases, and to date, multiple vaccines have been successfully used to protect against and eradicate both viral and bacterial pathogens. The main criterion of vaccine efficacy is the induction of specific humoral and cellular immune responses, and it is well established that immunogenicity depends on the type of vaccine as well as the route of delivery. In addition, antigen delivery to immune organs and the site of injection can potentiate efficacy of the vaccine. In light of this, microvesicles have been suggested as potential vehicles for antigen delivery as they can carry various immunogenic molecules including proteins, nucleic acids and polysaccharides directly to target cells. In this review, we focus on the mechanisms of microvesicle biogenesis and the role of microvesicles in infectious diseases. Further, we discuss the application of microvesicles as a novel and effective vaccine delivery system.

Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity

The responses of an activity-sensing rate-responsive system (Activitrax) to various forms of physiological activity were assessed in 15 individuals who had this pacemaker. Nine were patients with complete heart block and atrial arrhythmias; their mean age was 60 years (range, 41-85 years). Six were age-matched healthy volunteers who were exercised with an external Activitrax system attached firmly to the chest wall. The pacemaker was programmed to achieve a pacing rate of about 100 bpm at the end of the first stage of the Bruce protocol (pacemaker settings: rate = 70-150 bpm; threshold = low to medium; response = 6-9). In the activity-sensing ventricular pacing mode, all patients achieved a significant increase in treadmill time compared to constant-rate ventricular pacing (mean +/- SD, 8.0 +/- 3.3 vs 5.4 +/- 2.3 minutes; p less than 0.01), with a mean maximum pacing rate of 123 +/- 18 bpm. Jogging in place produced a prompt increase in pacing rate, with the maximum achieved at the end of the exercise. However, physiological activities such as hand-grip, the Valsalva maneuver and standing resulted in only minimal rate response. Pacing rate after ascending 4 flights of stairs was the same as that achieved after descending the same stairs (100 +/- 8 vs 105 +/- 4 bpm; p = 0.1). All 15 subjects were exercised from resting heart rate for 3 minutes on a treadmill at 1.2 mph and 2.5 mph with four gradients at each speed. Although the pacing rate increased with a faster treadmill speed (p less than 0.005), it did not respond appropriately to a change in gradient compared to the sinus rate. We conclude that although activity-sensing rate-responsive pacing gives a prompt increase in pacing rate and improves maximum exercise tolerance, further refinement is necessary because: (1) physiological activities not associated with significant movement are not detected by this pacing system; (2) detection of vibrations as an indicator of activities does not correlate well with the level of exertion.